$CBMX: Opened starter position.
Jason Napodano likes it at this price.
Chromosomal MicroArray (CMA) testing has been gaining widespread endorsement over the course of 2013 (College of Obstetricians and Gynecologists Association, Pediatrics Society, and NIH study demonstrating superiority over conventional karyotyping for prenatal testing).
Mainstream insurance companies have recently issued policy statements approving CMA as a first line test for prenatal testing for abnormalities and developmental post-natal testing - AETNA, Blue Cross/Blue Shield, United Healthcare, and other big names.
Financing of $12 million completed on December 17 at $2.06, puts a floor in the selling price for financiers. Should be sufficient cashflow to handle 24 months of operations under a no-growth scenario, while substantial growth is anticipated in 2014.
US Market for prenatal testing alone is somewhere between 80,000 (number of congenital abnormalities at birth) and 600,000 (number of high risk pregnancies out of 4 million births per year). CBMX has signed with major providers in the last 6 months a total of well over 50 million subscribers.
